Validation of Cytochrome P450 2C8 Inhibition AssayPublic
Downloadable Contentopen in viewer
One of the most important pharmaceutical properties of a drug candidate to be determined during any pre-clinical discovery is the effect of the specific test compound on the activity of Cytochrome P450, a key enzyme involved in drug metabolism. The purpose of this project was to validate a Cytochrome p450 2C8 (CYP2C8) enzyme inhibition assay in development at Charles River Labs (Worcester). The assay quantitates the in vitro inhibition of CYP2C8-specific drug substrates Amodiaquine (AMOD) and Paclitaxel (PACL). The data presented here validate the assay.
- This report represents the work of one or more WPI undergraduate students submitted to the faculty as evidence of completion of a degree requirement. WPI routinely publishes these reports on its website without editorial or peer review.
- Date created
- Resource type
- Rights statement
- In Collection:
|Thumbnail||Title||Visibility||Embargo Release Date||Actions|
Permanent link to this page: https://digital.wpi.edu/show/6w924d389